BIIB acquires NITE for $25.50/sh cash—a 68% premium to Friday’s close: https://globenewswire.com/news-release/2019/03/04/1745678/0/en/Biogen-Announces-Agreement-to-Acquire-Nightstar-Therapeutics-to-Establish-Clinical-Pipeline-of-Gene-Therapy-Candidates-in-Ophthalmology.html The nominal deal value is $877M.